Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve portfolios. Management credited strong On-X adoption, improved stent graft set sales, and a return to growth across international markets as key drivers behind the positive momentum. CEO Pat Mackin highlighted the recent FDA approval of the AMDS hybrid prosthesis and the acquisition of Endospan’s NEXUS system as important milestones, noting, “We are encouraged by our enduring fundamental strength and increasingly strong competitive advantages within this segment.”
Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).
Artivion (AORT) Q2 CY2026 Highlights:
- Revenue: $125.8 million vs analyst estimates of $120.5 million (11.3% year-on-year growth, 4.4% beat)
- Adjusted EPS: $0.13 vs analyst estimates of $0.10 (34.5% beat)
- Adjusted EBITDA: $26.38 million vs analyst estimates of $21.72 million (21% margin, 21.5% beat)
- The company reconfirmed its revenue guidance for the full year of $488 million at the midpoint
- EBITDA guidance for the full year is $95.5 million at the midpoint, above analyst estimates of $94.3 million
- Operating Margin: -6.7%, down from 7.4% in the same quarter last year
- Market Capitalization: $1.40 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Artivion’s Q2 Earnings Call
- Zachary Day (Canaccord Genuity) asked why guidance was not raised despite the revenue beat. CFO Lance Berry explained that stronger preservation services revenue was timing-related and that conservatism was warranted following a challenging first quarter.
- Shaymus Contorno (Oppenheimer) questioned what changed with AMDS adoption following FDA approval. CEO Pat Mackin described the waning of the $100,000 set price barrier and improved messaging as key factors.
- John McAulay (Stifel) inquired about the integration of Endospan and the outlook for scaling NEXUS. Mackin said prior partnerships eased integration, while Berry indicated that targeted hiring and training would support a focused U.S. launch in January 2027.
- Keith Hinton (Freedom Capital Markets) asked about the immediate impact of AMDS approval on account adoption. Berry clarified that no “bolus” of demand was expected, but that friction points had been removed for smoother account conversions.
- Joseph Conway (Needham & Company) asked about supply chain and international stent graft growth. Berry reported progress on supply recovery and noted improvement across all international regions, with contingency plans in place for the Israeli manufacturing site.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace of AMDS adoption and account conversions following its full U.S. approval, (2) progress toward the commercial launch of NEXUS in January 2027, including salesforce build-out and value analysis committee approvals, and (3) the continued expansion of On-X into new patient segments. Additional markers include supply chain normalization in the tissue business and ongoing enrollment in the ARTISAN clinical trial.
Artivion currently trades at $28.65, up from $26.57 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
